An editorial explains why discontinuation and carryover effects complicate interpretation when psychotropic regimens change.
The authors distinguish withdrawal reactions after stopping ongoing treatment from later relapse or recurrence of the underlying illness. They emphasize that a patient recently taken off medication is not necessarily equivalent to someone who has never received it. Earlier treatment can also continue exerting effects during a new regimen.
The editorial synthesizes evidence across several drug classes and does not test one benzodiazepine taper schedule. Its strongest use is identifying a design and clinical-reasoning issue. Symptoms appearing after a switch may reflect discontinuation, carryover, recurrence, the new medicine, or several together. Timing, previous duration, dose changes, and symptom character matter. A before-and-after narrative that ignores the stopping phase may incorrectly credit or blame the newly introduced treatment.
Original analysis of the supplied journal article, identified as PMC7176895.